State of the evidence: A 2026 mouse pharmacokinetic and tumor-model study; it does not directly measure human absorption.
What bioavailability asks
Finding material in the digestive tract is different from finding the same material in the circulation. The preparation may change, and a measurement may capture fragments rather than the original mixture. Asking what was measured is therefore essential. The conclusions become more precise only to the extent that the method distinguishes those possibilities. Measurement limitations are part of the result, not a detail to omit.
The main finding in the 2026 experiment
A 2026 mouse study reported systemic bioavailability below 0.01% after oral administration of a commercial MCP preparation. Oral treatment did not reduce tumor growth in the tested models, whereas intravenous findings differed.[1] This does not establish that every MCP preparation has zero absorption in people. It does challenge an automatic assumption that oral consumption provides meaningful systemic exposure.
Administration routes must remain separate
Oral and intravenous administration create different conditions. An effect observed with one route needs independent testing before being attributed to the other. In an article about supplements, presenting an experimental intravenous finding as evidence for oral effectiveness would be misleading. Comparing routes in a research paper is not a recommendation about use. Supplement products should not be used for injection, and this article provides no administration advice.
What a radiolabel can reveal
The researchers used radiolabeling and noted that the signal after oral administration might represent MCP-derived material rather than intact MCP.[1] That distinction does not invalidate the measurement; it defines its interpretation. Detecting a signal in blood or an image does not necessarily establish that the original functional material reached the target tissue. Additional evidence can be needed to connect those observations.
Moving from mice to people
Animal experiments can identify useful questions for subsequent research. Human studies still need to specify the preparation, measurement approach, timing and relevant outcomes. One animal model cannot settle every proposed use. Equally, a newer measurement that conflicts with an older assumption should be discussed openly. Both positive and negative results contribute to a clearer account of what remains uncertain.
Reading absorption claims carefully
When a description claims high bioavailability, look for a corresponding human measurement using the relevant preparation. Cell experiments, reduced molecular size and intravenous experiments do not independently establish oral human bioavailability. Greater absorption would not automatically mean greater benefit either: the desired outcome and safety need separate evaluation. This study should not be used to select a treatment or calculate a personal dose.
References
This article provides general health information. Research findings about MCP are not individual recommendations for diagnosing or treating disease. Medicine and supplement use should be discussed with a doctor or pharmacist.
Published and sources assessed: 17 October 2026